Annual report pursuant to Section 13 and 15(d)

EQUITY TRANSACTIONS (Details Narrative)

v3.22.2
EQUITY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Jun. 17, 2021
Jun. 15, 2021
Mar. 09, 2021
Apr. 30, 2019
Mar. 31, 2021
Jul. 31, 2021
Apr. 30, 2022
Jan. 31, 2022
Apr. 30, 2021
Class of Stock [Line Items]                  
Preferred stock, shares authorized             10,000,000 10,000,000 10,000,000
Preferred stock, par or stated value per share             $ 0.0001   $ 0.0001
Warrant terms             2 years 10 months 25 days    
Warrant [Member]                  
Class of Stock [Line Items]                  
Warrant terms             5 years   5 years
Exercise price (in dollars per share)             $ 6.25    
A L S F [Member]                  
Class of Stock [Line Items]                  
Shares purchase price       $ 15,000,000          
Warrant terms       12 months          
Securities Purchase Agreements [Member] | A L S F [Member]                  
Class of Stock [Line Items]                  
Number of shares purchase       10,000,000          
Shares purchase price       $ 15,000,000          
Shares purchase price (in dollars per share)       $ 1.50          
Securities Purchase Agreements [Member] | A L S F [Member] | Warrant [Member]                  
Class of Stock [Line Items]                  
Number of shares purchase       5,000,000          
Warrant terms       5 years          
Exercise price (in dollars per share)       $ 3.00          
Securities Purchase Agreements [Member] | Digital Power Lending [Member]                  
Class of Stock [Line Items]                  
Number of shares issued         6,666,667        
Proceeds from sale of equity         $ 10,000,000        
Shares issued price per share         $ 1.50        
Proceeds from related party     $ 4            
Advance from related parties     $ 1,800,000            
Description of purchase agreement terms         DPL (i) purchased an additional 1,333,333 shares of common stock upon approval by the FDA of the Company’s IND for its Phase IA clinical trials for AL001 for a purchase price of $2 million; and (ii) purchased 2,666,667 shares of Common Stock upon the completion of these Phase IA clinical trials for AL001 for a purchase price of $4 million. In addition, the Company issued DPL warrants to purchase an aggregate of 6,666,667 shares of common stock at an exercise price of $3.00 per share        
Securities Purchase Agreements [Member] | Digital Power Lending [Member] | Final Tranche [Member]                  
Class of Stock [Line Items]                  
Additional right to invest         $ 10,000,000 $ 10,000,000      
Securities Purchase Agreements [Member] | Ault Global [Member] | Convertible Promissory Note [Member]                  
Class of Stock [Line Items]                  
Number of shares issued     2,666,667            
Shares value surrender for cancellation     $ 50,000            
Securities Sold Agreements [Member]                  
Class of Stock [Line Items]                  
Number of shares purchase 375,000                
Number of shares sold 2,875,000                
Offering price (in dollars per share) $ 5.00                
Gross proceeds $ 14,400,000                
Proceeds from underwriting discount and estimated offering expenses $ 12,900,000                
Securities Purchase Agreement [Member] | Digital Power Lending [Member]                  
Class of Stock [Line Items]                  
Stock Issued During Period, Shares, Other 2,000,000 2,000,000     6,666,667        
Number of shares sold $ 10,000,000.0       $ 10,000,000        
Share price (in dollar per shares) $ 5.00 $ 5.00              
Series A Preferred Stock [Member]                  
Class of Stock [Line Items]                  
Preferred stock, shares authorized             8,640,000    
Preferred stock, par or stated value per share             $ 0.0001   $ 0.0001
Preferred stock shares designated             1,360,000   1,360,000
Preferred Shares converted into common stock             15,000,000